Related Experiment Video

Updated: Feb 1, 2026

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
07:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

3.0K

PARP inhibitors in ovarian cancer

Elisena Franzese1, Sara Centonze1, Anna Diana1

  • 1Division of Medical Oncology, Department of Precision Medicine, School of Medicine, "Luigi Vanvitelli" University of Campania, 80131 Naples, Italy.

Cancer Treatment Reviews
|December 14, 2018
PubMed

Insights

Poly-ADP-ribosepolymerase inhibitors (PARPis) offer effective treatment for ovarian cancer, particularly in cases with DNA repair deficiencies. Future strategies involve combining PARPis with other agents to enhance efficacy and broaden clinical application.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Epithelial ovarian cancer (EOC) presents significant genetic complexity, often involving DNA damage repair pathway alterations.
  • Homologous recombination (HR) deficiency is a key feature in nearly half of EOC cases, influencing therapeutic response.

Purpose of the Study:

  • To review current clinical trial data for approved Poly-ADP-ribosepolymerase inhibitors (PARPis) in ovarian cancer.
  • To explore future combination strategies for PARPis to overcome resistance and expand treatment options.

Main Methods:

  • Review of recent clinical trial results for olaparib, niraparib, and rucaparib in ovarian cancer.
  • Analysis of emerging combination therapies including antiangiogenic and immunocheckpoint inhibitors.

Main Results:

  • PARPis have demonstrated significant efficacy in treating ovarian cancer, especially in HR-deficient tumors.
  • Current data supports PARPis as a cornerstone therapy, altering clinical management.

Conclusions:

  • Approved PARPis (olaparib, niraparib, rucaparib) have transformed ovarian cancer treatment.
  • Future research directions include combining PARPis with other agents to improve outcomes in both HR-deficient and non-deficient tumors.
Keywords:
NiraparibOlaparibOvarian cancerPARP inhibitorsRucaparib

More Related Videos

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

2.3K
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.7K

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
3.9K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
669
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
6.9K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.5K